Foscan® contains temoporfin, a photosensitizing agent, activated with non-thermal light at a wavelength of 652 nm delivered by a laser after 4 days of intravenous administration of the drug.

Foscan® has received Indian marketing autorization for the palliative treatment of patients with advanced squamous cell carcinoma of the head and neck who have failed prior therapies and are unsuitable for radiotherapy,surgery or systemic chemotherapy.

Foscan® is marketed in India through Advanced Clinical Research (P) Ltd.